BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kang J, Toita R, Murata M. Liver cell-targeted delivery of therapeutic molecules. Critical Reviews in Biotechnology 2013;36:132-43. [DOI: 10.3109/07388551.2014.930017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 He Y, Chen J, Ma Y, Chen H. Apolipoproteins: New players in cancers. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1051280] [Reference Citation Analysis]
2 Luo F, Yu Y, Li M, Chen Y, Zhang P, Xiao C, Lv G. Polymeric nanomedicines for the treatment of hepatic diseases. J Nanobiotechnol 2022;20:488. [DOI: 10.1186/s12951-022-01708-y] [Reference Citation Analysis]
3 Warner JB, Guenthner SC, Hardesty JE, McClain CJ, Warner DR, Kirpich IA. Liver-specific drug delivery platforms: Applications for the treatment of alcohol-associated liver disease. World J Gastroenterol 2022; 28(36): 5280-5299 [DOI: 10.3748/wjg.v28.i36.5280] [Reference Citation Analysis]
4 Peng Y, Cong Y, Lei Y, Sun F, Xu M, Zhang J, Fang L, Hong H, Cai T. Transforming Passive into Active: Multimodal Pheophytin-Based Carbon Dots Customize Protein Corona to Target Metastatic Breast Cancer. Adv Healthc Mater 2022;11:e2102270. [PMID: 35032116 DOI: 10.1002/adhm.202102270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yang S, Cai C, Wang H, Ma X, Shao A, Sheng J, Yu C. Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal 2022;20. [DOI: 10.1186/s12964-021-00796-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Wan Y, Li X, Slevin E, Harrison K, Li T, Zhang Y, Klaunig JE, Wu C, Shetty AK, Dong XC, Meng F. Endothelial dysfunction in pathological processes of chronic liver disease during aging. FASEB J 2022;36:e22125. [PMID: 34958687 DOI: 10.1096/fj.202101426R] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Moosavian SA, Sathyapalan T, Jamialahmadi T, Sahebkar A. The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review. Bioinorg Chem Appl 2021;2021:4041415. [PMID: 34659388 DOI: 10.1155/2021/4041415] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
8 Kumar V, Rahman M, Gahtori P, Al-Abbasi F, Anwar F, Kim HS. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine. Expert Opin Drug Deliv 2021;18:673-94. [PMID: 33295218 DOI: 10.1080/17425247.2021.1860939] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Fleischmann D, Maslanka Figueroa S, Goepferich A. Steric Shielding of cRGD-Functionalized Nanoparticles from Premature Exposition to Off-Target Endothelial Cells under a Physiological Flow. ACS Appl Bio Mater 2021;4:640-50. [DOI: 10.1021/acsabm.0c01193] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Sun H, Chang L, Yan Y, Wang L. Hepatitis B virus pre-S region: Clinical implications and applications. Rev Med Virol 2020. [PMID: 33314434 DOI: 10.1002/rmv.2201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Li X, Hu X, Pan T, Dong L, Ding L, Wang Z, Song R, Wang X, Wang N, Zhang Y, Wang J, Yang B. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway. Biomed Pharmacother 2021;133:110802. [PMID: 33202286 DOI: 10.1016/j.biopha.2020.110802] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
12 Hartl N, Adams F, Merkel OM. From adsorption to covalent bonding: Apolipoprotein E functionalization of polymeric nanoparticles for drug delivery across the blood-brain barrier. Adv Ther (Weinh) 2021;4:2000092. [PMID: 33542947 DOI: 10.1002/adtp.202000092] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 17.5] [Reference Citation Analysis]
13 Dehshahri A, Sadeghpour H, Mohazzabieh E, Saatchi Avval S, Mohammadinejad R. Targeted double domain nanoplex based on galactosylated polyethylenimine enhanced the delivery of IL ‐12 plasmid. Biotechnol Progress 2020;36. [DOI: 10.1002/btpr.3002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Maklakova SY, Naumenko VA, Chuprov AD, Mazhuga MP, Zyk NV, Beloglazkina EK, Majouga AG. Cellular uptake of N-acetyl-d-galactosamine-, N-acetyl-d-glucosamine- and d-mannose-containing fluorescent glycoconjugates investigated by liver intravital microscopy. Carbohydrate Research 2020;489:107928. [DOI: 10.1016/j.carres.2020.107928] [Reference Citation Analysis]
15 Böttger R, Pauli G, Chao PH, Al Fayez N, Hohenwarter L, Li SD. Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev 2020;154-155:79-101. [PMID: 32574575 DOI: 10.1016/j.addr.2020.06.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 17.0] [Reference Citation Analysis]
16 Chew SA, Moscato S, George S, Azimi B, Danti S. Liver Cancer: Current and Future Trends Using Biomaterials. Cancers (Basel) 2019;11:E2026. [PMID: 31888198 DOI: 10.3390/cancers11122026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
17 Li Y, Wei J, Wei Y, Cheng L, Guo B, Meng F, Li F, Zhong Z. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma. Biomacromolecules 2020;21:716-24. [DOI: 10.1021/acs.biomac.9b01419] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
18 Tramontano E, Corona A, Menéndez-Arias L. Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus. Antiviral Res 2019;171:104613. [PMID: 31550450 DOI: 10.1016/j.antiviral.2019.104613] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
19 Lee AR, Nam K, Lee BJ, Lee SW, Baek SM, Bang JS, Choi SK, Park SJ, Kim TH, Jeong KS, Lee DY, Park JK. Hepatic Cellular Distribution of Silica Nanoparticles by Surface Energy Modification. Int J Mol Sci 2019;20:E3812. [PMID: 31387201 DOI: 10.3390/ijms20153812] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 Baig B, Halim SA, Farrukh A, Greish Y, Amin A. Current status of nanomaterial-based treatment for hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2019;116:108852. [DOI: 10.1016/j.biopha.2019.108852] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 20.3] [Reference Citation Analysis]
21 Ma Z, Zhang B, Fan Y, Wang M, Kebebe D, Li J, Liu Z. Traditional Chinese medicine combined with hepatic targeted drug delivery systems: A new strategy for the treatment of liver diseases. Biomed Pharmacother 2019;117:109128. [PMID: 31234023 DOI: 10.1016/j.biopha.2019.109128] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
22 Hu M, Huang L. Nanomaterial Manipulation of Immune Microenvironment in the Diseased Liver. Adv Funct Mater 2018. [DOI: 10.1002/adfm.201805760] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
23 Hunt NJ, McCourt PAG, Le Couteur DG, Cogger VC. Novel targets for delaying aging: The importance of the liver and advances in drug delivery. Adv Drug Deliv Rev 2018;135:39-49. [PMID: 30248361 DOI: 10.1016/j.addr.2018.09.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
24 Zhang X, Zhu L, Zhou Y, Shi A, Wang H, Han M, Wan X, Kilonzo SB, Luo X, Chen T, Ning Q. Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice. BMC Immunol 2018;19:20. [PMID: 29940856 DOI: 10.1186/s12865-018-0256-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
25 Liu Y, Wang H, Zhou L, Su Y, Shen W. Biodistribution, activation, and retention of proinsulin-transferrin fusion protein in the liver: Mechanism of liver-targeting as an insulin prodrug. Journal of Controlled Release 2018;275:186-91. [DOI: 10.1016/j.jconrel.2018.02.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
26 Zhang Y, Zhou T, Luo L, Cui Z, Wang N, Shu Y, Wang K. Pharmacokinetics, biodistribution and receptor mediated endocytosis of a natural Angelica sinensis polysaccharide. Artificial Cells, Nanomedicine, and Biotechnology 2018;46:254-63. [DOI: 10.1080/21691401.2017.1421210] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
27 Paolini M, Poul L, Berjaud C, Germain M, Darmon A, Bergère M, Pottier A, Levy L, Vibert E. Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel. Int J Nanomedicine 2017;12:5537-56. [PMID: 28814868 DOI: 10.2147/IJN.S141145] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
28 Toita R, Kawano T, Murata M, Kang J. Anti-obesity and anti-inflammatory effects of macrophage-targeted interleukin-10-conjugated liposomes in obese mice. Biomaterials 2016;110:81-8. [DOI: 10.1016/j.biomaterials.2016.09.018] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
29 Xie Y, Liu D, Cai C, Chen X, Zhou Y, Wu L, Sun Y, Dai H, Kong X, Liu P. Size-dependent cytotoxicity of Fe3O4 nanoparticles induced by biphasic regulation of oxidative stress in different human hepatoma cells. Int J Nanomedicine 2016;11:3557-70. [PMID: 27536098 DOI: 10.2147/IJN.S105575] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
30 Xue WJ, Feng Y, Wang F, Guo YB, Li P, Wang L, Liu YF, Wang ZW, Yang YM, Mao QS. Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma. Sci Rep 2016;6:22149. [PMID: 26915683 DOI: 10.1038/srep22149] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
31 Toita R, Kawano T, Kang JH, Murata M. Applications of human hepatitis B virus preS domain in bio- and nanotechnology. World J Gastroenterol 2015; 21(24): 7400-7411 [PMID: 26139986 DOI: 10.3748/wjg.v21.i24.7400] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
32 Jin S, Lin X, Guan H, Wu J. Cell-specific expression of the analgesic-antitumor peptide coding sequence under the control of the human α-fetoprotein gene promoter and enhancer. Exp Ther Med 2015;9:863-7. [PMID: 25667643 DOI: 10.3892/etm.2015.2166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]